Lexaria Bioscience (LEXX) Competitors $0.85 -0.02 (-2.52%) As of 03:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LEXX vs. GANX, DTIL, RLMD, GNTA, CUE, INKT, TVRD, ANL, NRXP, and ICCCShould you be buying Lexaria Bioscience stock or one of its competitors? The main competitors of Lexaria Bioscience include Gain Therapeutics (GANX), Precision BioSciences (DTIL), Relmada Therapeutics (RLMD), Genenta Science (GNTA), Cue Biopharma (CUE), MiNK Therapeutics (INKT), Tvardi Therapeutics (TVRD), Adlai Nortye (ANL), NRx Pharmaceuticals (NRXP), and ImmuCell (ICCC). These companies are all part of the "pharmaceutical products" industry. Lexaria Bioscience vs. Its Competitors Gain Therapeutics Precision BioSciences Relmada Therapeutics Genenta Science Cue Biopharma MiNK Therapeutics Tvardi Therapeutics Adlai Nortye NRx Pharmaceuticals ImmuCell Gain Therapeutics (NASDAQ:GANX) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation. Does the media refer more to GANX or LEXX? In the previous week, Gain Therapeutics had 9 more articles in the media than Lexaria Bioscience. MarketBeat recorded 13 mentions for Gain Therapeutics and 4 mentions for Lexaria Bioscience. Gain Therapeutics' average media sentiment score of 0.78 beat Lexaria Bioscience's score of 0.42 indicating that Gain Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexaria Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is GANX or LEXX more profitable? Gain Therapeutics has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,849.19%. Lexaria Bioscience's return on equity of -157.22% beat Gain Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gain TherapeuticsN/A -289.10% -155.11% Lexaria Bioscience -1,849.19%-157.22%-133.69% Do insiders and institutionals have more ownership in GANX or LEXX? 12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 7.2% of Gain Therapeutics shares are owned by company insiders. Comparatively, 26.4% of Lexaria Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, GANX or LEXX? Gain Therapeutics has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Do analysts recommend GANX or LEXX? Gain Therapeutics presently has a consensus price target of $7.86, indicating a potential upside of 320.17%. Lexaria Bioscience has a consensus price target of $4.00, indicating a potential upside of 369.48%. Given Lexaria Bioscience's higher possible upside, analysts plainly believe Lexaria Bioscience is more favorable than Gain Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gain Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger valuation and earnings, GANX or LEXX? Lexaria Bioscience has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGain Therapeutics$50K1,344.53-$20.41M-$0.63-2.97Lexaria Bioscience$460K36.23-$5.80M-$0.67-1.27 SummaryLexaria Bioscience beats Gain Therapeutics on 9 of the 16 factors compared between the two stocks. Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LEXX vs. The Competition Export to ExcelMetricLexaria BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.67M$3.40B$6.05B$10.51BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-1.2723.0384.9327.30Price / Sales36.23268.08515.79197.96Price / CashN/A46.9537.5761.53Price / Book1.7810.5412.426.82Net Income-$5.80M-$52.58M$3.32B$276.59M7 Day Performance-6.34%0.59%0.53%0.00%1 Month Performance-34.46%15.50%10.24%7.96%1 Year Performance-70.31%18.01%75.92%35.10% Lexaria Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LEXXLexaria Bioscience2.8489 of 5 stars$0.85-2.5%$4.00+369.5%-71.4%$16.67M$460K-1.277GANXGain Therapeutics2.9489 of 5 stars$1.84-3.4%$7.86+327.9%-13.2%$66.00M$50K-2.9120Analyst ForecastGap DownDTILPrecision BioSciences3.8318 of 5 stars$5.55-0.2%$47.00+747.0%-34.3%$65.54M$68.70M-0.63200RLMDRelmada Therapeutics2.7533 of 5 stars$1.96-3.2%$1.00-48.8%-42.4%$64.89MN/A-0.8810GNTAGenenta Science0.915 of 5 stars$3.48+7.1%N/A-46.3%$63.65MN/A0.007Gap DownHigh Trading VolumeCUECue Biopharma2.5047 of 5 stars$0.82+0.7%N/A-34.1%$63.09M$9.29M-1.4760News CoveragePositive NewsAnalyst ForecastINKTMiNK Therapeutics2.8988 of 5 stars$13.94-1.1%$37.50+169.1%+108.1%$62.99MN/A-4.8430TVRDTvardi Therapeutics2.899 of 5 stars$6.50-2.8%$55.50+753.8%N/A$60.97M$7.14M0.0080Trending NewsAnalyst DowngradeHigh Trading VolumeANLAdlai Nortye1.6749 of 5 stars$1.65+3.0%$9.00+447.1%-14.3%$60.70M$5M0.00127NRXPNRx Pharmaceuticals3.3154 of 5 stars$3.03-2.9%$34.50+1,038.6%+131.1%$60.02MN/A-1.352ICCCImmuCell1.1285 of 5 stars$6.62-2.7%N/A+82.6%$59.87M$26.49M34.8270Gap Up Related Companies and Tools Related Companies GANX Competitors DTIL Competitors RLMD Competitors GNTA Competitors CUE Competitors INKT Competitors TVRD Competitors ANL Competitors NRXP Competitors ICCC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LEXX) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
